Altria's US-only cigarette business faces persistent volume declines (5-7% annually) partially offset by pricing. NJOY e-vapor acquisition and on! oral nicotine provide reduced-risk product optionality but execution and scale lag Philip Morris's ZYN. Marlboro pricing power remains durable. Dividend yield of 7%+ supports valuation floor but limits upside. Watch for FDA marketing decisions on next-gen products.